Theralase Technologies Inc. Commences Equity Financing



    TORONTO, June 4 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT & OTC BB:
TLTFF) announces that it is undertaking a non-brokered equity financing to
raise up to $5 million.
    The Company is offering units at a price of $0.50 per unit. Each unit
will be comprised of one common share and one half of a non-transferable share
purchase warrant. Each whole warrant will entitle the holder to purchase one
additional common share at an exercise price of $0.75 per share, for a period
of one year from the date of closing. The offering is expected to commence on
June 4th, 2007 and the company anticipates closing the offering on or about
June 29th, 2007. All Theralase directors are participating in this private
placement offering.
    The company intends to utilize the proceeds of the offering for US market
expansion, TLC-2000 biomedical laser commercialization, TLC-2000 biomedical
laser clinical study and TLC-3000 Photodynamic Compound and biomedical laser
research and development.

    Theralase Technologies Inc. designs, develops, manufactures and sells
leading edge, proprietary, high powered, super-pulsed therapeutic laser
equipment employed in a wide range of biostimulative medical therapy
applications. The Theralase technology platform targets several diverse
healthcare sectors -- firstly, for non-invasive pain management, control and
therapy, including a wide range of neural-musculo-skeletal conditions,
arthritic and rheumatologic disorders -- secondly, to bio-stimulate and
accelerate wound care and healing, including: bone fracture regeneration and
osteoarthritic conditions -- and thirdly, combining proprietary metallic
complexes with photo-dynamic lasers to attack specifically-targeted cancerous
growths. For a complete profile of Theralase Technologies Inc. and its
products visit www.theralase.com.
    For a complete profile of Theralase Technologies Inc. and its products
visit www.theralase.com.

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of the contents of this
    release.





For further information:

For further information: Roger Dumoulin-White, President & CEO, Phone:
(905) 947-8455, e-mail: rwhite@theralase.com

Organization Profile

THERALASE TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890